Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Mcclure · SciRah

Researcher profile · Semantic Scholar

T. Mcclure

Share profile

T. Mcclure — researcher profile on SciRah

h-index: 10
Works: 24
Citations: 653

Most-cited papers

Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
C. Campbell, Hugh J. McMillan, Jean K. Mah, M. Tarnopolsky +6 more
2017Muscle and Nerve223 citations
Semantic Scholar
A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers
K. Attie, M. Allison, T. Mcclure, I. Boyd +3 more
2014American journal of hematology/oncology115 citations Open access
Semantic Scholar
A prospective study of the removal rate of imaged breast lesions by an 11-gauge vacuum-assisted biopsy probe system.
R. Fine, P. Israel, Lise C Walker, K. Corgan +6 more
2001American Journal of Surgery64 citations
Semantic Scholar
Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial
L. Dunbar, J. Milata, T. Mcclure, Margaret M. Wasilewski
2011Antimicrobial Agents and Chemotherapy63 citations Open access
Semantic Scholar
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
J. Bendell, M. Gordon, H. Hurwitz, S. Jones +11 more
2013Clinical Cancer Research61 citations Open access
Semantic Scholar
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.
T. Yap, H. Burris, S. Kummar, G. Falchook +16 more
201830 citations
Semantic Scholar
Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer
P. LoRusso, I. Krop, K. Miller, Cynthia X. Ma +10 more
201525 citations
Semantic Scholar
A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
R. Kurzrock, E. Galanis, D. Johnson, V. Kansra +4 more
201415 citations
Semantic Scholar
P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)
F. Palandri, D. Ross, T. Cochrane, C. Tate +24 more
2021HemaSphere12 citations Open access
Semantic Scholar
LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
E. Coakley, A. Ahmad, Kajal B. Larson, T. Mcclure +9 more
2019Open Forum Infectious Diseases10 citations Open access
Semantic Scholar
P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS
H. Gill, A. Yacoub, K. Pettit, T. Bradley +32 more
2022HemaSphere9 citations Open access
Semantic Scholar
A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).
L. Sequist, I. Anderson, N. Demars, E. Felip +11 more
20165 citations
Semantic Scholar
A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors
S. Isakoff, R. Bahleda, M. Saleh, R. Bordoni +7 more
20165 citations
Semantic Scholar
EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study
V. Ratziu, M. Rinella, B. Tetri, E. Lawitz +11 more
2020Journal of Hepatology3 citations Open access
Semantic Scholar
Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.
A. Jimeno, M. Posner, J. Weiss, L. Wirth +14 more
20143 citations
Semantic Scholar
A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.
M. Atkins, M. Voss, E. Plimack, B. Rini +11 more
20143 citations
Semantic Scholar
Abstract CT189: Improved progression-free and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial
T. Yap, J. Gainor, M. Callahan, G. Falchook +18 more
2019Clinical Trials2 citations
Semantic Scholar
Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.
W. Harb, A. Adjei, M. Beeram, J. Pipas +7 more
20162 citations
Semantic Scholar
Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
A. Jimeno, L. Wirth, M. Posner, R. Cohen +15 more
20132 citations
Semantic Scholar
Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.
M. Atkins, R. Bhatt, M. Voss, B. Rini +10 more
20131 citations
Semantic Scholar
J005 An update on select-hd, which is evaluating an allele-selective mutant huntingtin lowering approach in Huntington’s disease
Asela Bandara, Oksana Suchowersky, Ralf Reilmann, T. Mestre +11 more
2024J: Clinical therapeutics0 citations Open access
Semantic Scholar
Clinical Efficacy, Safety and Pharmacokinetic Profile of EDP-938, A Novel RSV N-Inhibitor, in a Healthy Volunteer Challenge Study
E. Coakley, A. Ahmad, K. Larson, K. Lin +4 more
2020D16. INSIGHTS FROM CLINICAL STUDIES AND DATABASES IN PNEUMONIA0 citations
Semantic Scholar
Abstract 4053: Genetic and molecular profiling of ICOS hi CD4 T cells demonstrates clonal expansion of Th1 effector cells following JTX-2011 treatment in subjects with solid tumors
Christopher D. Harvey, Amanda Hanson, Martin Y. Fan, L. McGrath +9 more
2019Immunology0 citations
Semantic Scholar
A phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wildtype metastatic colorectal cancer (mCRC).
E. Chan, W. Harb, K. Mody, Xiao-Yu Jiang +7 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Wilson×7
Invite
D. Wilson — researcher profile on SciRah
M. Sherman×7
Invite
M. Sherman — researcher profile on SciRah
K. Attie×6
Invite
K. Attie — researcher profile on SciRah
S. Pandya×4
Invite
S. Pandya — researcher profile on SciRah

×3

Invite

P. LoRusso — researcher profile on SciRah

Invite

E. Hooper — researcher profile on SciRah

Invite

N. Adda — researcher profile on SciRah

Invite

W. Harb — researcher profile on SciRah

Amelia E. Pearsall×2

Invite

Amelia E. Pearsall — researcher profile on SciRah

Carolyn H. Condon×2

Invite

Carolyn H. Condon — researcher profile on SciRah

Invite

T. Yap — researcher profile on SciRah

Invite

H. Burris — researcher profile on SciRah